Skip to content
OpenCapital
Get started

Baxter International BAX Chronic Renal — Net Sales

Discontinued — last reported Q2 '24

Other product segments

Infusion Therapies & Technologies
$981M-1.3%
Care & Connectivity Solutions
$435M+1.9%
Drug Compounding
$320M+30.1%
Advanced Surgery
$304M+13.4%
Injectables & Anesthesia
$301M-10.1%
Front Line Care
$270M-2.5%

Similar metrics at other companies

DaVita logo
DVAU.S.Dialysis And Related Lab Services — Revenue
$2.92B+3.9%
DaVita logo
DVAOther - Ancillary Services — Dialysis patient service revenues
$248.18M+18.3%
DaVita logo
DVAUS Dialysis And Related Lab Services — Health Care Organization Revenue
$2.52B+11.5%
DaVita logo
DVAOther Operating Segments with Intersegment — Dialysis patient service revenues
$357.84M+20.3%
DaVita logo
DVAU S Dialysis And Related Lab Services with Intersegment — Dialysis patient service revenues
$2.82B+2.4%
DaVita logo
DVAU S Dialysis And Related Lab Services with Intersegment — Total revenues
$2.82B+2.4%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%—
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0×0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Baxter International’s 10-Q, filed August 6, 2024, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's chronic renal — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's chronic renal — net sales?
Baxter International (BAX) reported chronic renal — net sales of $917M in Q2 2024.
How has Baxter International's chronic renal — net sales changed year-over-year?
Baxter International's chronic renal — net sales increased by 11562.5% year-over-year, from -$8M to $917M.
What does chronic renal — net sales mean?
Total revenue earned from products and services used to treat patients with chronic kidney failure.
How do you interpret chronic renal — net sales?
An increase indicates growing demand for chronic dialysis solutions or successful market penetration, while a decrease may signal competitive pressure, pricing headwinds, or shifts in patient treatment modalities.
How does chronic renal — net sales compare across companies?
Comparable to renal care or dialysis-specific revenue segments reported by major medical device competitors and specialized dialysis service providers.